08:14 AM EDT, 09/09/2024 (MT Newswires) -- Terns Pharmaceuticals ( TERN ) said Monday that a phase 1 study of its obesity drug candidate TERN-601 yielded "positive" results.

The trial showed that the drug candidate, intended for obesity and overweight in adults, was well tolerated and led to "statistically significant" weight loss compared with placebo.

The company said the highest dose of 740 mg of its drug candidate resulted in nearly 5% weight loss, with 67% of participants losing 5% or more of their baseline body weight.

Tern Pharmaceuticals said it plans to advance TERN-601 to phase 2 clinical trials in 2025.

Shares of the company rose more than 28% in recent premarket activity Monday.

Price: 10.06, Change: +2.25, Percent Change: +28.81